Uncategorized – Page 9

Researchers Say Psychological Response To Genetic Counseling And Multigene Panel Testing For Hereditary Cancer Risk Tied To Test Results And Demonstrated Low Distress And Uncertainty

Posted on February 15, 2021 by Womens Cancer Care

Cancer Network (2/9, Slater) reports researchers found that “among an ethnically and socioeconomically diverse population of individuals undergoing genetic counseling and multigene panel testing for hereditary cancer risk…psychological response corresponded to test results and demonstrated low distress and uncertainty.” The findings were published in Cancer. […]

Researchers Examine Prevalence, Risk Factors, And Prognostic Value Of Chemotherapy-Associated VTE In Patients With Ovarian Cancer

Posted on February 10, 2021 by Womens Cancer Care

Cancer Network (2/8, Fowler) reports researchers examined “the prevalence, risk factors, and prognostic value of chemotherapy-associated venous thromboembolism (VTE) in patients with ovarian cancer” and “found a pooled prevalence of 9% for this group of patients.” In addition, “the data also found substantial risk factors for chemotherapy-related VTE, potentially assisting future efforts to target preventative measures […]

Oral Contraceptive Use Associated With Decreased Risk Of Ovarian Cancer, Endometrial Cancer Three Decades After Discontinuation

Posted on February 5, 2021 by Womens Cancer Care

MD Edge ObGyn (2/3, Remaly) reports, “Oral contraceptive use is associated with a decreased risk of ovarian and endometrial cancer 3 decades after discontinuation, according to an analysis of data from more than 250,000 women.” Furthermore, “oral contraceptive use is associated with a short-term increased risk of breast cancer after discontinuation, although the lifetime risk of […]

MRI Can Be Used To Assess Cervical Neuroendocrine Carcinoma

Posted on February 4, 2021 by Womens Cancer Care

Diagnostic Imaging (2/2, Palmer) reports a new study suggests MRI can be used to identify and accurately assess neuroendocrine carcinoma (NEC) in the uterine cervix. Researchers in Japan “enrolled 62 women, ranging from ages 26 to 82, who had histologically surgery-proven uterine cervical NEC, and examined them with T2-weighted MRI,” determining that “among the 50 women in […]

Majority Of Patients With Cancer Are Unfamiliar With Complementary, Integrative Therapies

Posted on February 3, 2021 by Womens Cancer Care

The ASCO Post (2/1, Stenger) reports a single-institution study at the University Hospitals Seidman Cancer Center in Cleveland, Ohio “found that a high proportion of patients with cancer and their caregivers were unfamiliar with available complementary and integrative medicine services.” Patients were surveyed “about five complementary and integrative medicine therapies – acupuncture, massage, meditation, music therapy, and yoga,” […]

Addition Of Wee1 Inhibitor To Gemcitabine Reduces Risk Of Disease Progression And Death In Women With Recurrent, Platinum-Resistant Or -Refractory Ovarian Cancer In Phase 2 Trial

Posted on January 28, 2021 by Womens Cancer Care

MedPage Today (1/25, Ingram) reports researchers found in a phase 2 trial that the addition of “the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer.” The trial’s results were published in The Lancet. […]

US Reports Another Record One-Year Decline In Cancer Death Rate From 2017 To 2018

Posted on January 13, 2021 by Womens Cancer Care

The AP (1/12, Stobbe) reports the US “reported another record one-year decline in the…cancer death rate, a drop they attribute to success against lung cancer.” The US cancer death rate has been decreasing since 1991, and “from 2017 to 2018, it fell 2.4%, according to an American Cancer Society report, topping the record 2.2% drop reported the year […]

CRT Improves DFS And OS In Patients With Stage IIIB Cervical Cancer In Long-Term Follow-Up To Phase 3 Trial

Posted on January 8, 2021 by Womens Cancer Care

Cancer Therapy Advisor (1/7, Lawrence) reports researchers found in a long-term follow-up of a phase 3 trial that “in addition to improving disease-free survival (DFS), chemoradiotherapy (CRT) resulted in an overall survival (OS) benefit for patients with stage IIIB cervical cancer.” The researchers say the results “reinforce the evidence that CRT for the treatment of stage […]

Decline In Preventative Cancer Screenings Due To Pandemic May Have Serious Implications For Years To Come

Posted on January 5, 2021 by Womens Cancer Care

Forbes (1/4) contributor Alice Broster writes, “In early 2020 many hospitals and clinics put preventative cancer screenings on hold due to the pandemic” and instead urged the use of “telehealth services as much as possible.” Broster adds that although “many clinics have opened their doors for cancer screenings again research suggests there’s been a drop in […]

FDA Approves Drug For Treatment Of Advanced Breast Cancer

Posted on December 17, 2020 by Womens Cancer Care

Reuters (12/16, Maddipatla) reports, “MacroGenics Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had approved its drug Margenza in combination with chemotherapy for the treatment of an advanced type of breast cancer in patients who failed two or more prior therapies.” The company “said it was expecting to launch the drug in March.” Cancer […]